Oxidative stress and @entity32 have recently been linked to @entity16 in essential @entity101 (EH). Activated peripheral polymorphonuclear leukocytes (PMN) damage surrounding tissue by releasing reactive @entity26 species (ROS) and proteolytic enzymes before self- @entity39 . PMN @entity39 further exacerbates @entity32 and promotes @entity6722 and PMN recruitment. The number and properties of PMN from untreated EH @entity1 is the focus of the present study. Oxidative stress was assessed by measuring the rate of @entity224 anion release from separated, @entity4621 -stimulated PMN and the redox state of plasma @entity2041 . Inflammation was estimated indirectly by determining PMN number and their in vitro survival. PMN from EH @entity1 (n = 37) released @entity224 anion faster (P < .0001) than those of normotensives (NC, n = 37), 17.7 +/- 1.14 v 9.54 +/- 0.51 nmol/10 min/10(6) cells. The redox state of @entity2041 was twofold higher in EH plasma (P < .02) indicating systemic oxidative stress. PMN survival in vitro correlates linearly with the rate of @entity224 release (r2 = 0.60, P < .02) and PMN count of EH @entity1 , although in the normal range, were significantly higher (P < .0001), indicating @entity39 and recruitment. @entity101 plasma significantly reduced NC PMN viability, whereas normal plasma significantly increased EH PMN viability. What our studies show is that EH is accompanied by a primed state PMN that does not correlate with the levels of blood pressure. PMN priming in EH @entity1 reflects an in vivo exposure to a constant stimulus ending in oxidative stress, @entity39 , and cell recruitment. Oxidative stress and @entity32 will result in @entity16 and @entity731 in the long run.

Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and XXXX in @entity1 with essential @entity101 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity6722 :: ('MESH:C565534', 'Disease') :: ['chemotaxis'] @entity101 :: ('MESH:D006973', 'Disease') :: ['Hypertensive', 'hypertension'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis', 'increased self-necrosis'] @entity16 :: ('MESH:D009422', 'Disease') :: ['endothelial damage'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione'] @entity4621 :: ('CHEBI:37532', 'Chemical') :: ['phorbol ester'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']
@entity32 :: (MESH:D007249,Disease) :: ['inflammation']
